The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer.

Using a genome-wide cDNA microarray to search for genes that were specifically up-regulated in non-small cell lung cancers (NSCLC), we identified an abundant expression of neuromedin U (NMU) in the great majority of lung cancers. Immunohistochemical analysis showed a significant association of NMU expression with poorer prognosis of patients with NSCLC. Treatment of NSCLC cells with short interfering RNA against NMU suppressed its expression and inhibited the growth of the cells; on the other hand, the induction of exogenous expression of NMU conferred growth-promoting activity and enhanced cell mobility in vitro. We found that two G protein-coupled receptors, growth hormone secretagogue receptor 1b and neurotensin receptor 1, were also overexpressed in NSCLC cells, and that a heterodimer complex of these receptors functioned as an NMU receptor. The NMU-receptor interaction subsequently induced the generation of a second messenger, cyclic AMP, to activate its downstream genes including transcription factors and cell cycle regulators. Treatment of NSCLC cells with short interfering RNAs for growth hormone secretagogue receptor or neurotensin receptor 1 suppressed the expression of those genes and the growth of NSCLC cells. These data strongly implied that targeting the NMU signaling pathway would be a promising therapeutic strategy for the treatment of lung cancers.

[1]  N. Bunnett,et al.  Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. , 1997, The Biochemical journal.

[2]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[3]  R. Osamura,et al.  Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas , 2001, Clinical endocrinology.

[4]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  O. Nishimura,et al.  Identification of Neuromedin U as the Cognate Ligand of the Orphan G Protein-coupled Receptor FM-3* , 2000, The Journal of Biological Chemistry.

[7]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[8]  A. Beaudet,et al.  Ligand-induced internalization of neurotensin in transfected COS-7 cells: differential intracellular trafficking of ligand and receptor. , 2000, Journal of cell science.

[9]  U. Kumar,et al.  Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.

[10]  C. Caldas,et al.  A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples , 2003, Molecular pathology : MP.

[11]  A. Datta,et al.  Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.

[12]  C. Delporte,et al.  Ghrelin is produced by the human erythroleukemic HEL cell line and involved in an autocrine pathway leading to cell proliferation. , 2005, Endocrinology.

[13]  G. Sozzi.  Molecular biology of lung cancer. , 2001, European journal of cancer.

[14]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[15]  L. Thim,et al.  Rabbit neuromedin U-25: lack of conservation of a posttranslational processing site , 1991, Regulatory Peptides.

[16]  D. Schöevaërt,et al.  Pathways of internalization of the hCG/LH receptor: immunoelectron microscopic studies in Leydig cells and transfected L-cells , 1992, The Journal of cell biology.

[17]  R. Zeillinger,et al.  Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. , 2005, Oncology reports.

[18]  C. H. Cheng,et al.  Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli , 2004, Molecular and Cellular Endocrinology.

[19]  David E. Misek,et al.  Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. , 2003, The American journal of pathology.

[20]  L. Heasley,et al.  Autocrine and paracrine signaling through neuropeptide receptors in human cancer , 2001, Oncogene.

[21]  M. Ghatei,et al.  Characterization of neuromedin U like immunoreactivity in rat, porcine, guinea-pig and human tissue extracts using a specific radioimmunoassay. , 1986, Biochemical and biophysical research communications.

[22]  M. Nakazato,et al.  Purification and identification of neuromedin U as an endogenous ligand for an orphan receptor GPR66 (FM3). , 2000, Biochemical and biophysical research communications.

[23]  Yusuke Nakamura,et al.  Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. , 2005, Cancer research.

[24]  Yusuke Nakamura,et al.  ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. , 2005, Cancer research.

[25]  G. Yancopoulos,et al.  Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Teh,et al.  FOXM1 is a downstream target of Gli1 in basal cell carcinomas. , 2002, Cancer research.

[27]  S. Legon,et al.  Distribution and developmental pattern of neuromedin U expression in the rat gastrointestinal tract. , 1994, Journal of molecular endocrinology.

[28]  Yusuke Nakamura,et al.  ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer , 2004, Clinical Cancer Research.

[29]  Y. Yiangou,et al.  The distribution, purification, and pharmacological action of an amphibian neuromedin U. , 1989, The Journal of biological chemistry.

[30]  Christopher P. Austin,et al.  Identification of receptors for neuromedin U and its role in feeding , 2000, Nature.

[31]  A. Gewirtz,et al.  Neuromedin U: a Myb-regulated autocrine growth factor for human myeloid leukemias. , 2004, Blood.

[32]  J. Polak,et al.  Localization of 7B2, neuromedin B, and neuromedin U in specific cell types of rat, mouse, and human pituitary, in rat hypothalamus, and in 30 human pituitary and extrapituitary tumors. , 1988, Endocrinology.

[33]  Carlos Caldas,et al.  Molecular Classification of Breast Carcinomas Using Tissue Microarrays , 2003, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[34]  C. Lawrence,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society doi: 10.1210/en.2002-220121 Evaluation of Neuromedin U Actions in Energy Homeostasis and Pituitary Function , 2022 .

[35]  F. Monsma,et al.  Cloning and characterization of murine neuromedin U receptors , 2002, Peptides.

[36]  Michel Bouvier,et al.  Oligomerization of G-protein-coupled transmitter receptors , 2001, Nature Reviews Neuroscience.

[37]  Yusuke Nakamura,et al.  Advances in Brief Identification of COX 17 as a Therapeutic Target for Non-Small Cell Lung Cancer 1 , 2003 .

[38]  N. Minamino,et al.  Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. , 1985, Biochemical and biophysical research communications.

[39]  Teuvo Kohonen,et al.  The self-organizing map , 1990 .

[40]  S. Bloom,et al.  Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. , 1995, Journal of molecular endocrinology.

[41]  J. Edwardson,et al.  Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.

[42]  A. Beaudet,et al.  Somatodendritic internalization and perinuclear targeting of neurotensin in the mammalian brain , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  加藤 達哉.  A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis , 2005 .

[44]  M. Ikawa,et al.  Neuromedin U has a novel anorexigenic effect independent of the leptin signaling pathway , 2004, Nature Medicine.

[45]  Yusuke Nakamura,et al.  Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. , 2005, Cancer research.

[46]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[47]  L. Devi,et al.  Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. , 2001, Trends in pharmacological sciences.

[48]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[49]  H. Lother,et al.  AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration , 2000, Nature.